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Off-Label Drug Uses
Pimozide: Parasitosis (Delusional) Joyce A. Generali, RPh, MS, FASHP (Editor), * and Dennis J. Cada, PharmD, FASHP, FASCP †
BACKGROUND
Delusional parasitosis or infestation is an uncommon disorder in which patients believe they are infested with pathogens (eg, insects, parasites, or vermin) accompanied by abnormal skin sensations (eg, crawling, tingling). 1, 2 Symptoms are persistent and often cause the patient to seek medical attention from a variety of physicians before diagnosis is established. Delusional parasitosis occurs more frequently in women than in men, with a typical onset in middle age. It may be chronic or episodic and has been classifi ed as primary or secondary (eg, drug or disease induced). Various treatment modalities have been recommended, including psychotherapy and pharmacological agents. In various pharmacological therapy overviews, the use of antipsychotics with or without antidepressants has been recognized as primary therapy in addition to treatment of any underlying disease.
PATIENT POPULATION
Adult patients with delusional parasitosis.
DOSAGE AND DURATION
Initial doses of 1 to 2 mg daily are titrated slowly (1 mg every 5 to 7 days) to the effective dose that is best tolerated. Typical maintenance doses are between 2 and 4 mg daily. The lowest possible dose of pimozide should be used for the shortest duration, with periodic assessment to determine tolerance and response. Duration documented in the literature has been from a few months to over a year.
RESULTS
A lack of well-controlled trials may be attributed to the diffi culty in collecting patients with parasitosis, as this is not a common disorder. Pimozide for the treatment of delusional parasitosis is based primarily on data from case series/reports that demonstrate some effi cacy in the majority of patients. The use of the drug is limited by its side-effect profi le.
Controlled Trials
In a double-blind, placebo-controlled, crossover trial, 11 patients (mean age, 65.6 years; range, 45-83 years) with delusional parasitosis were treated with pimozide (1-5 mg daily) or placebo for 6 weeks separated by a 4-week washout period. The initial pimozide dose was 2 mg daily and was adjusted at 2 weeks based upon effi cacy and tolerance. Two patients did not complete the study. All patients were evaluated at baseline and weekly intervals for subjective (eg, itch, feeling of vermin) and objective symptoms (eg, excoriations and delusions). Pimozide was signifi cantly better than placebo in relieving itch delusions, but it was no different than placebo for feelings of vermin or excoriations. In addition, when compared to placebo, pimozide signifi cantly decreased the Brief Psychiatric Rating Scale score from baseline to end of treatment (mean * Editor-in-Chief, Hospital Pharmacy, and Clinical Professor, Emeritus, Department of Pharmacy Practice, University of Kansas, School of Pharmacy, Kansas City/Lawrence, Kansas, e-mail: jgeneral@ku.edu; † Founder and Contributing Editor, The Formulary, and Editor, Off-Label Drug Facts, e-mail: Dennis.Cada@wolterskluwer.com. reduction, 13.5 vs 1.3; P = .012). This study was limited by poor methodology description and small sample size. 3
Case Series/Reports
In a case series of 33 patients with delusional parasitosis (median age, 60 years), pimozide was prescribed for 24 patients, 18 of whom took the drug. The dose ranged from 1 to 5 mg daily. No information regarding initial dosing was specifi ed, although the dose was continued for 6 weeks prior to tapering. Of those patients receiving pimozide, 61% (11/18) experienced improvement in or full remission of symptoms; the remaining 39% (7) experienced no change in symptoms. Onset in symptom improvement was noted within 3 to 4 weeks in responders. For those patients not receiving pimozide, only 20% (3/15) experienced relief or resolution of symptoms. This report was limited by poor description of other treatments, lack of specifi c methodology, and small sample size. 4 In several case reports, pimozide has been effective in partially or completely resolving symptoms in the majority of adult patients treated for delusional parasitosis. Daily doses in these reports have ranged from 1 to 5 mg in most cases, but they have been as high as 8 mg, with various adjustment schedules based on tolerance and effi cacy. In responders, onset of symptom relief has occurred in 10 days to 4 weeks. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 
SAFETY
This is a limited safety profi le. Refer to package labeling for complete prescribing information (eg, Warnings/Precautions, Adverse Reactions, Drug Interactions).
Adverse effects that have occurred in the reviewed data include extrapyrimadal symptoms and QT prolongation. 5, 7, 10 
THERAPY CONSIDERATIONS
Pimozide for the treatment of delusional parasitosis is based primarily on data from case series/ reports that demonstrate some effi cacy in the major-ity of patients. The use of the drug is limited by its side-effect profi le.
